TPD approaches have great potential to transform the treatment of a range of diseases. Amphista is advancing a portfolio of drug candidates, initially focused in oncology, to address a number of hard to treat tumour types. Our lead candidates are designed to address areas of high unmet medical need where there is a clear and compelling rationale why our approach will be superior to any existing approaches and treatments.
Identifying Biological Targets and Disease where Amphista Approaches will be Best-in-Class
The superiority of Amphista degraders is based on combinations of the three key factors shown below:
- The benefits of degrading, rather than just inhibiting, the drug target,
- The benefits of using our unique, novel Amphista mode of action and
- Our improved druglike properties allowing convenient dosing routes and access to cells and tissues not possible with other approaches.
We focus on tackling biological targets and mechanisms with a high level of clinical or genetic validation expected to translate to a clear benefit in a well-defined set of patients.
We expect our lead project to be ready for clinical trials in 2023. Our approach is also applicable to treatment of a wide variety of diseases. We plan to expand our work into additional therapy areas which may include neurological & neurodegenerative conditions, immunology & anti-infectives and are open to partnerships in these areas.